Follow us on:

Drug Data Shouldn’t Be Secret

By PETER DOSHI and TOM JEFFERSON  Published: April 10, 2012  The New York Times – IN the fall of 2009, at the height of fears over swine flu, our research group discovered that a majority of clinical trial data for the anti-influenza drug Tamiflu — data that proved, according to its manufacturer, that the drug reduced the risk of hospitalization, serious complications and transmission — were missing, unpublished and inaccessible to the research community. From what we could tell from the limited clinical data that had been published in medical journals, the country’s most widely used and heavily stockpiled influenza drug appeared no more effective than aspirin Read More

This entry was posted in Headline of the Day, Patient Safety Activism and tagged , , , , , . Bookmark the permalink.